{"transactions":[{"id":721609,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T23:04:56.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":10833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":238334,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":10833},"source":{"system":"sec-edgar","filing":"0001628280-26-046654","document":"wk-form4_1782947093.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000162828026046654/wk-form4_1782947093.xml","form_type":"4"}},{"id":721608,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:56.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":10833,"price":16.0242,"value":173590.1586,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 8,961 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c)."}],"balance_after":8961,"source":{"system":"sec-edgar","filing":"0001628280-26-046654","document":"wk-form4_1782947093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000162828026046654/wk-form4_1782947093.xml","form_type":"4"}},{"id":721607,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-07-01T23:04:56.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":10833,"price":4.5,"value":48748.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":19794,"source":{"system":"sec-edgar","filing":"0001628280-26-046654","document":"wk-form4_1782947093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000162828026046654/wk-form4_1782947093.xml","form_type":"4"}},{"id":874834,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-02T23:28:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":3611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":249167,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":3611},"source":{"system":"sec-edgar","filing":"0001437749-26-006421","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926006421/rdgdoc.xml","form_type":"4"}},{"id":874833,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-03-02T23:28:58.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3611,"price":15.0153,"value":54220.2483,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-26-006421","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926006421/rdgdoc.xml","form_type":"4"}},{"id":874832,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-03-02T23:28:58.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":3611,"price":4.5,"value":16249.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":3611,"source":{"system":"sec-edgar","filing":"0001437749-26-006421","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926006421/rdgdoc.xml","form_type":"4"}},{"id":927267,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-30","kind":"grant","planned":true,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service."}],"balance_after":160000,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":927266,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-28","kind":"exercise","planned":true,"acquired":false,"shares":3611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":252778,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":3611},"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":927265,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-28","kind":"sale","planned":true,"acquired":false,"shares":811,"price":14.4848,"value":11747.1728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":927264,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-28","kind":"sale","planned":true,"acquired":false,"shares":2800,"price":14.0861,"value":39441.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $14.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":811,"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":927263,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2026-01-30T21:52:05.000Z","date":"2026-01-28","kind":"exercise","planned":true,"acquired":true,"shares":3611,"price":4.5,"value":16249.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":3611,"source":{"system":"sec-edgar","filing":"0001437749-26-002575","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774926002575/rdgdoc.xml","form_type":"4"}},{"id":957372,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-30T21:12:15.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":false,"shares":3611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":256389,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":3611},"source":{"system":"sec-edgar","filing":"0001437749-25-038938","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925038938/rdgdoc.xml","form_type":"4"}},{"id":957371,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2025-12-30T21:12:15.000Z","date":"2025-12-29","kind":"sale","planned":true,"acquired":false,"shares":3611,"price":12.0627,"value":43558.4097,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-25-038938","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925038938/rdgdoc.xml","form_type":"4"}},{"id":957370,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Class A Common Stock","published_at":"2025-12-30T21:12:15.000Z","date":"2025-12-29","kind":"exercise","planned":true,"acquired":true,"shares":3611,"price":4.5,"value":16249.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":3611,"source":{"system":"sec-edgar","filing":"0001437749-25-038938","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925038938/rdgdoc.xml","form_type":"4"}},{"id":1164998,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-28T20:21:48.000Z","date":"2025-04-28","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted outside of the Plan, pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). This grant is subject to a performance-based vesting condition to be satisfied upon the achievement of a particular clinical milestone, based on such performance condition being satisfied within two years of the grant date and subject to the Reporting Person's continuous service."}],"balance_after":26000,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001437749-25-013340","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925013340/rdgdoc.xml","form_type":"4"}},{"id":1164997,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":34127,"kind":"person","name":"Watkins Tim","position":1,"cik":"0002065965","reported_name":"Watkins Tim","relationship":{"officer":true,"officer_title":"CMO & Head of Development"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-28T20:21:48.000Z","date":"2025-04-28","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted outside of the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the inducement grant exception under Nasdaq Marketplace Rule 5635(c)(4). One-half of the option shares vest on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":260000,"derivative":{"exercise_price":4.5,"expiration_date":"2035-04-27","underlying":"Class A Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001437749-25-013340","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2065965/000143774925013340/rdgdoc.xml","form_type":"4"}}]}